-
- ADME/DMPK for Stroke DrugsDrug Efficacy Testing for Stroke
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral TestingBrain Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
Safety Assessment for Stroke DrugsIn Vitro Pharmacology for Stroke Drugs- Cell Viability Assay
- Caspase-3 Activity Assay
- In Vitro Neuroinflammatory Models and Assays
- Excitotoxicity In Vitro Assay
- Cell-Based Mitochondrial Function Assay
- In Vitro Oxidative Stress Assay
- Analysis of Ischemia-Triggered Glutamate Excitotoxicity
- NMDA Receptor-mediated Excitotoxicity
- AMPA Receptor-mediated Excitotoxicity
Molecular Mechanism Analysis of Oxidative Stress in StrokeAnalysis of Neuroinflammatory Mechanisms in Stroke- Molecular Mechanism Analysis of Ischemia-Reperfusion Injury
Cell Death Mechanism Analysis in Stroke- Autophagy Mechanism Analysis in StrokeApoptotic Mechanism Analysis after Cerebral Ischemia
- Ferroptosis Pathways
- Necroptosis Signaling Pathways
Epigenetic Mechanism Analysis in Stroke- Analysis of Gut Microbiota in Stroke
- Animal Modeling of Stroke
- Animal Modeling of Ischemic StrokeAnimal Modeling of Hemorrhagic StrokeIn Vitro Modeling of Stroke
- In Vitro Modeling of Ischemic Stroke
- In Vitro Modeling of Hemorrhagic Stroke
- Small-Molecule Antiplatelet DrugsNeuroprotective PeptidesMonoclonal Antibodies for StrokeStem Cell-Based Therapies for StrokeDrug Delivery SystemsInquiry
Drug Delivery System Development for Stroke
To date, thrombolytic therapy is the only FDA-approved clinical treatment for ischemic stroke. In addition, physiological barriers complicate the development of therapeutic and diagnostic interventions related for stroke. Therefore, new technologies that enable targeted drug delivery to specific brain regions, selective drug release, and improved drug bioavailability hold promise as effective adjunctive therapies for stroke. Researchers working to improve drug delivery to ischemic stroke sites have developed many effective strategies to address the limitations of drug therapy.
Fig. 1. Schematic diagrams of a smart drug delivery system targeting ischemic stroke. (Wu et al., 2020) Our Drug Delivery System Development Services
Ace Therapeutics is a leading provider of stroke drug development services. We help clients develop innovative drug delivery solutions for stroke. Our scientists have many years of experience in the development of drug delivery systems. Our services include custom design, flexible developing, and preclinical research of delivery systems, with aim to help clients accelerate the development of stroke therapies.
We can develop multiple types of drug delivery systems to meet the needs of clients.
Nanoparticle-Based Drug Delivery System Development Services
Nanoparticles can increase the concentration of a drug on the surface of cells in the BBB, or the nanoparticles can increase the circulation time in the blood, giving the drug more opportunities to cross the BBB. Ace Therapeutics offers comprehensive services to help clients develop feasible and effective nanoparticle-based drug delivery systems to deliver stroke drugs to targeted ischemic brain regions.
Liposome-Based Drug Delivery System Development Services
Ace Therapeutics provides reliable strategies for liposome design and drug efficacy data and drug efficacy data to assist clients in the development of liposome-based drug delivery systems. These liposome-based drug delivery systems allow stroke drugs to cross the blood-brain barrier and also protect stroke drugs from degradation by the biological environment, thereby increasing circulation time and accumulation in target tissues.
Exosome-Based Drug Delivery System Development Services
Exosomes have the advantages of biocompatibility, biological stability and targeting as drug delivery carriers. In addition, Exosomes are involved in increasing long-term neuroprotection after stroke, promoting nerve regeneration, enhancing neurological recovery, and regulating peripheral immune responses. Based on the understanding of the role of exosomes in cerebral ischemia, Ace Therapeutics offers a range of services to help clients develop exosome-based drug delivery systems for stroke.
Nasal Drug Delivery System Development Services
Nasal drug delivery of a variety of therapeutic compounds, including small chemicals, large proteins, and even stem cells, has proven to be highly effective in bypassing the BBB. Ace Therapeutics offers comprehensive nasal drug delivery system development services to pharmaceutical companies focused on stroke. Working together, our professionals can optimize nasal drug delivery systems and develop new drug formulations to make stroke drugs suitable for intranasal delivery.
Virus-Based Gene Delivery System Development Services
Gene delivery system design is the key to gene therapy for stroke. Ace Therapeutics offers reliable virus-based gene delivery system development services to help clients accelerate the development of gene therapy for stroke. Our team of experts utilizes molecular biology, viral vector design techniques, RNA sequencing, and bioinformatics to design and develop virus-based gene delivery systems to meet the unique needs of pharmaceutical companies.
Why Choose Our Drug Delivery Development Services
We use advanced technologies and materials to help pharmaceutical companies and stroke-focused research institutions develop more efficient and convenient drug delivery systems. These systems contribute to:
- Control the release of drugs
- Provide targeted drug delivery
- Enhance water solubility and stability of drugs and regulate drug metabolism time
- Improve drug bioavailability
- Increase the ability to transport drugs across the BBB
- Enhance drug absorption
- Reduce drug side effects
Ace Therapeutics is a partner that can provide one-stop services from drug delivery system design and development to preclinical research. Integrating our drug delivery system development services into the early stages of stroke drug development can reduce the overall time and cost of the drug development lifecycle. Please contact us to learn more. We look forward to working with you!
Reference- Wu, Q., et al. (2020). Probing the drug delivery strategies in ischemic stroke therapy. Drug Delivery, 27(1), 1644-1655.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.Related Services
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket